SCHEMBL6941664

SCHEMBL6941664

O=C(O)C=CSc1nc2ccccc2o1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.62
MAPT P10636 3/20 0.62
MAPK1 P28482 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
KMT2A Q03164 6/20 0.52
MEN1 O00255 4/20 0.52
HPGD P15428 3/20 0.52
NPC1 O15118 2/20 0.52
ALDH1A1 P00352 5/20 0.51
SMN1; SMN2 Q16637 4/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
TSHR P16473 2/20 0.49
GFER P55789 1/20 0.49
POLB P06746 2/20 0.45
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6941663 1.00 RAB9A (0.62) RAB9AMAPTMAPK1NPSR1KMT2A
SCHEMBL28051063 0.78 RAB9A (0.48) RAB9AMAPTMAPK1NPSR1KMT2A
SCHEMBL3176468 0.76 KMT2A (0.59) RAB9AMAPTNPSR1KMT2AMEN1
SCHEMBL31293729 0.74 DDAH1 (0.51) RAB9AMAPTMAPK1NPSR1KMT2A
SCHEMBL8383277 0.74 DDAH1 (0.51) RAB9AMAPTMAPK1NPSR1KMT2A
SCHEMBL10758194 0.74 KMT2A (0.50) RAB9AMAPTMAPK1NPSR1KMT2A
SCHEMBL10758191 0.74 KMT2A (0.50) RAB9AMAPTMAPK1NPSR1KMT2A
SCHEMBL3534983 0.73 HDAC3 (0.72) RAB9AMAPTKMT2AMEN1HPGD
SCHEMBL3534981 0.73 HDAC3 (0.72) RAB9AMAPTKMT2AMEN1HPGD
SCHEMBL9305001 0.73 KMT2A (0.56) RAB9AMAPTMAPK1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642246-B1 Potent ligands for nicotinic acetylcholine receptors (nAChRs). Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's ASTRAZENECA AB (SE) 2003-11-04 US disclosed
EP-1235826-B1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2003-09-03 EP disclosed
EP-1235826-A1 QUINUCLIDINE ACRYLAMIDES AstraZeneca AB (SE) 2002-09-04 EP disclosed
WO-2001029034-A1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2001-04-26 WO disclosed